{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:19:06Z","timestamp":1788941946728,"version":"build-2803163510"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To conduct a systematic review of the comparative efficacy of various psychotropic medications for the treatment of disruptive behavior (DBs) in youths. To this aim, we systematically reviewed randomized clinical trials (RCTs) of various psychotropic medications targeting symptoms of DBs and applied network meta-analysis to investigate their relative efficacy. Fifty-five RCTs meeting the inclusion criteria were selected. To predict and interpret relative treatment efficacy, we compared the efficacy of various psychotropic medications prescribed for DB symptoms based on their mechanism\u00a0of\u00a0action. Network meta-analysis revealed that for reducing DBs, second-generation antipsychotics, stimulants, and non-stimulant ADHD medications were more efficacious than placebo, and second-generation antipsychotics were the most efficacious. The dopaminergic modulation of top-down inhibitory process by these medications is discussed in this review. This study offers information on the relative efficacy of various psychotropic medications for the treatment of DB, and insight into a potential neurobiological underpinning for those symptoms. It also illustrates the potential utility of these neurobiological mechanisms as a target for future treatment studies.<\/jats:p>","DOI":"10.1038\/s41598-023-33979-2","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T06:04:45Z","timestamp":1682661885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Psychopharmacological treatment of disruptive behavior in youths: systematic review and network meta-analysis"],"prefix":"10.1038","volume":"13","author":[{"given":"Ji-Woo","family":"Seok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigette","family":"Soltis-Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatiya","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J. R.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonjo","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"1","key":"33979_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pedn.2007.10.007","volume":"24","author":"SM Breitenstein","year":"2009","unstructured":"Breitenstein, S. M., Hill, C. & Gross, D. Understanding disruptive behavior problems in preschool children. J. Pediatr. Nurs. 24(1), 3\u201312 (2009).","journal-title":"J. Pediatr. Nurs."},{"issue":"4","key":"33979_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1017\/S0954579400007367","volume":"8","author":"DS Shaw","year":"1996","unstructured":"Shaw, D. S., Owens, E. B., Vondra, J. I., Keenan, K. & Winslow, E. B. Early risk factors and pathways in the development of early disruptive behavior problems. Dev. Psychopathol. 8(4), 679\u2013699 (1996).","journal-title":"Dev. Psychopathol."},{"issue":"1","key":"33979_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/15374410701820117","volume":"37","author":"SM Eyberg","year":"2008","unstructured":"Eyberg, S. M., Nelson, M. M. & Boggs, S. R. Evidence-based psychosocial treatments for children and adolescents with disruptive behavior. J. Clin. Child Adolesc. Psychol. 37(1), 215\u2013237 (2008).","journal-title":"J. Clin. Child Adolesc. Psychol."},{"key":"33979_CR4","doi-asserted-by":"crossref","unstructured":"Milone, A., Sesso, G. Disruptive Behavior Disorders: Symptoms, Evaluation and Treatment. 225 (Multidisciplinary Digital Publishing Institute, 2022).","DOI":"10.3390\/brainsci12020225"},{"key":"33979_CR5","unstructured":"Campbell, S. B. Behavior Problems in Preschool Children: Clinical and Developmental Issues. (Guilford Press, 2006)."},{"issue":"1","key":"33979_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1037\/0033-2909.94.1.68","volume":"94","author":"R Loeber","year":"1983","unstructured":"Loeber, R. & Dishion, T. Early predictors of male delinquency: A review. Psychol. Bull. 94(1), 68 (1983).","journal-title":"Psychol. Bull."},{"issue":"7","key":"33979_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/jclp.22274","volume":"72","author":"FT Bonadio","year":"2016","unstructured":"Bonadio, F. T., Dynes, M., Lackey, J., Tompsett, C. & Amrhein, K. Grouping youth with similar symptoms: A person-centered approach to transdiagnostic subgroups. J. Clin. Psychol. 72(7), 676\u2013688 (2016).","journal-title":"J. Clin. Psychol."},{"issue":"2","key":"33979_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11121-011-0201-1","volume":"14","author":"ST Lanza","year":"2013","unstructured":"Lanza, S. T. & Rhoades, B. L. Latent class analysis: An alternative perspective on subgroup analysis in prevention and treatment. Prev. Sci. 14(2), 157\u2013168 (2013).","journal-title":"Prev. Sci."},{"issue":"3","key":"33979_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.comppsych.2013.11.001","volume":"55","author":"J Brodbeck","year":"2014","unstructured":"Brodbeck, J. et al. The structure of psychopathological symptoms and the associations with DSM-diagnoses in treatment seeking individuals. Compr. Psychiatry 55(3), 714\u2013726 (2014).","journal-title":"Compr. Psychiatry"},{"issue":"6","key":"33979_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler, R. C., Chiu, W. T., Demler, O. & Walters, E. E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 617\u2013627 (2005).","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"33979_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s13311-017-0549-4","volume":"14","author":"SC Cook","year":"2017","unstructured":"Cook, S. C., Schwartz, A. C. & Kaslow, N. J. Evidence-based psychotherapy: Advantages and challenges. Neurotherapeutics 14(3), 537\u2013545 (2017).","journal-title":"Neurotherapeutics"},{"issue":"1","key":"33979_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/00004583-200101000-00015","volume":"40","author":"JM Thomas","year":"2001","unstructured":"Thomas, J. M. & Guskin, K. A. Disruptive behavior in young children: What does it mean?. J. Am. Acad. Child Adolesc. Psychiatry 40(1), 44\u201351 (2001).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"7","key":"33979_CR13","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jpsychires.2012.03.022","volume":"46","author":"A Vander Stoep","year":"2012","unstructured":"Vander Stoep, A. et al. Identifying comorbid depression and disruptive behavior disorders: Comparison of two approaches used in adolescent studies. J. Psychiatr. Res. 46(7), 873\u2013881 (2012).","journal-title":"J. Psychiatr. Res."},{"issue":"5","key":"33979_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/BF01670101","volume":"24","author":"GJ August","year":"1996","unstructured":"August, G. J., Realmuto, G. M., MacDonald, A. W., Nugent, S. M. & Crosby, R. Prevalence of ADHD and comorbid disorders among elementary school children screened for disruptive behavior. J. Abnorm. Child Psychol. 24(5), 571\u2013595 (1996).","journal-title":"J. Abnorm. Child Psychol."},{"issue":"2","key":"33979_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.beth.2019.07.004","volume":"51","author":"JL Hawks","year":"2020","unstructured":"Hawks, J. L., Kennedy, S. M., Holzman, J. B. & Ehrenreich-May, J. Development and application of an innovative transdiagnostic treatment approach for pediatric irritability. Behav. Ther. 51(2), 334\u2013349 (2020).","journal-title":"Behav. Ther."},{"issue":"4","key":"33979_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175651","volume":"12","author":"I-J Hsieh","year":"2017","unstructured":"Hsieh, I.-J. & Chen, Y. Y. Determinants of aggressive behavior: Interactive effects of emotional regulation and inhibitory control. PLoS\u00a0One 12(4), e0175651 (2017).","journal-title":"PLoS\u00a0One"},{"issue":"11","key":"33979_CR17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrn3577","volume":"14","author":"RJR Blair","year":"2013","unstructured":"Blair, R. J. R. The neurobiology of psychopathic traits in youths. Nat. Rev. Neurosci. 14(11), 786\u2013799 (2013).","journal-title":"Nat. Rev. Neurosci."},{"issue":"11","key":"33979_CR18","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/cercor\/bht154","volume":"24","author":"JT Buhle","year":"2014","unstructured":"Buhle, J. T. et al. Cognitive reappraisal of emotion: A meta-analysis of human neuroimaging studies. Cereb. Cortex 24(11), 2981\u20132990 (2014).","journal-title":"Cereb. Cortex"},{"issue":"7","key":"33979_CR19","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1017\/S0033291716000118","volume":"46","author":"S Hwang","year":"2016","unstructured":"Hwang, S. et al. Dual neurocircuitry dysfunctions in disruptive behavior disorders: Emotional responding and response inhibition. Psychol. Med. 46(7), 1485\u20131496 (2016).","journal-title":"Psychol. Med."},{"issue":"2","key":"33979_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bandc.2004.09.016","volume":"56","author":"KR Ridderinkhof","year":"2004","unstructured":"Ridderinkhof, K. R., Van Den Wildenberg, W. P., Segalowitz, S. J. & Carter, C. S. Neurocognitive mechanisms of cognitive control: The role of prefrontal cortex in action selection, response inhibition, performance monitoring, and reward-based learning. Brain Cogn. 56(2), 129\u2013140 (2004).","journal-title":"Brain Cogn."},{"issue":"2","key":"33979_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.bandc.2009.04.004","volume":"71","author":"VM Goghari","year":"2009","unstructured":"Goghari, V. M. & MacDonald, A. W. III. The neural basis of cognitive control: Response selection and inhibition. Brain Cogn. 71(2), 72\u201383 (2009).","journal-title":"Brain Cogn."},{"issue":"2","key":"33979_CR22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bbr.2011.10.049","volume":"231","author":"M Potegal","year":"2012","unstructured":"Potegal, M. Temporal and frontal lobe initiation and regulation of the top-down escalation of anger and aggression. Behav. Brain Res. 231(2), 386\u2013395 (2012).","journal-title":"Behav. Brain Res."},{"issue":"11","key":"33979_CR23","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41593-020-00715-2","volume":"23","author":"JE Lischinsky","year":"2020","unstructured":"Lischinsky, J. E. & Lin, D. Neural mechanisms of aggression across species. Nat. Neurosci. 23(11), 1317\u20131328 (2020).","journal-title":"Nat. Neurosci."},{"issue":"5","key":"33979_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/15374416.2015.1038827","volume":"44","author":"TP Beauchaine","year":"2015","unstructured":"Beauchaine, T. P. Future directions in emotion dysregulation and youth psychopathology. J. Clin. Child Adolesc. Psychol. 44(5), 875\u2013896 (2015).","journal-title":"J. Clin. Child Adolesc. Psychol."},{"issue":"5","key":"33979_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.avb.2008.06.003","volume":"13","author":"D Seo","year":"2008","unstructured":"Seo, D., Patrick, C. J. & Kennealy, P. J. Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress. Violent. Behav. 13(5), 383\u2013395 (2008).","journal-title":"Aggress. Violent. Behav."},{"issue":"4\u20136","key":"33979_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0893-6080(02)00052-7","volume":"15","author":"ND Daw","year":"2002","unstructured":"Daw, N. D., Kakade, S. & Dayan, P. Opponent interactions between serotonin and dopamine. Neural Netw. 15(4\u20136), 603\u2013616 (2002).","journal-title":"Neural Netw."},{"key":"33979_CR27","unstructured":"Jalain, C. I. The impact of serotonin and dopamine on human aggression: A systematic review of the literature. (2014)."},{"issue":"1","key":"33979_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1089\/cap.2018.0076","volume":"29","author":"H-H Shih","year":"2019","unstructured":"Shih, H.-H., Shang, C.-Y. & Gau, S. S. F. Comparative efficacy of methylphenidate and atomoxetine on emotional and behavioral problems in youths with attention-deficit\/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 29(1), 9\u201319 (2019).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"9","key":"33979_CR29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.biopsych.2006.12.030","volume":"62","author":"DR Coghill","year":"2007","unstructured":"Coghill, D. R., Rhodes, S. M. & Matthews, K. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit\/hyperactivity disorder. Biol. Psychiat. 62(9), 954\u2013962 (2007).","journal-title":"Biol. Psychiat."},{"issue":"6","key":"33979_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jaac.2016.03.014","volume":"55","author":"KD Gadow","year":"2016","unstructured":"Gadow, K. D. et al. Severely aggressive children receiving stimulant medication versus stimulant and risperidone: 12-month follow-up of the TOSCA trial. J. Am. Acad. Child Adolesc. Psychiatry 55(6), 469\u2013478 (2016).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"3","key":"33979_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1207\/s15374424jccp2003_9","volume":"20","author":"SP Hinshaw","year":"1991","unstructured":"Hinshaw, S. P. Stimulant medication and the treatment of aggression in children with attentional deficits. J. Clin. Child Adolesc. Psychol. 20(3), 301\u2013312 (1991).","journal-title":"J. Clin. Child Adolesc. Psychol."},{"issue":"2","key":"33979_CR32","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1542\/peds.2006-1880","volume":"121","author":"ME Bangs","year":"2008","unstructured":"Bangs, M. E. et al. Atomoxetine for the treatment of attention-deficit\/hyperactivity disorder and oppositional defiant disorder. Pediatrics 121(2), e314\u2013e320 (2008).","journal-title":"Pediatrics"},{"issue":"11","key":"33979_CR33","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.euroneuro.2009.07.008","volume":"19","author":"G Dell'Agnello","year":"2009","unstructured":"Dell\u2019Agnello, G. et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study. Eur. Neuropsychopharmacol. 19(11), 822\u2013834 (2009).","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"33979_CR34","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1542\/peds.114.1.e1","volume":"114","author":"DK Kelsey","year":"2004","unstructured":"Kelsey, D. K. et al. Once-daily atomoxetine treatment for children with attention-deficit\/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 114(1), e1\u2013e8 (2004).","journal-title":"Pediatrics"},{"issue":"4","key":"33979_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/00004583-200004000-00021","volume":"39","author":"RL Findling","year":"2000","unstructured":"Findling, R. L. et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J. Am. Acad. Child Adolesc. Psychiatry 39(4), 509\u2013516 (2000).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"8","key":"33979_CR36","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","volume":"159","author":"MG Aman","year":"2002","unstructured":"Aman, M. G. et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am. J. Psychiatry. 159(8), 1337\u20131346 (2002).","journal-title":"Am. J. Psychiatry."},{"issue":"9","key":"33979_CR37","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","volume":"41","author":"R Snyder","year":"2002","unstructured":"Snyder, R. et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J. Am. Acad. Child Adolesc. Psychiatry 41(9), 1026\u20131036 (2002).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"2","key":"33979_CR38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1089\/cap.2006.0007","volume":"18","author":"DF Connor","year":"2008","unstructured":"Connor, D. F., McLaughlin, T. J. & Jeffers-Terry, M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J. Child Adolesc. Psychopharmacol. 18(2), 140\u2013156 (2008).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"7","key":"33979_CR39","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/archpsyc.57.7.649","volume":"57","author":"RP Malone","year":"2000","unstructured":"Malone, R. P., Delaney, M. A., Luebbert, J. F., Cater, J. & Campbell, M. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch. Gen. Psychiatry 57(7), 649\u2013654 (2000).","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"33979_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4088\/JCP.v62n0405","volume":"62","author":"JK Buitelaar","year":"2001","unstructured":"Buitelaar, J. K., Van der Gaag, R. J. & Melman, C. T. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J. Clin. Psychiatry 62(4), 239\u2013248 (2001).","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"33979_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/cap.2008.044","volume":"19","author":"DP Dickstein","year":"2009","unstructured":"Dickstein, D. P. et al. Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. J. Child Adolesc. Psychopharmacol. 19(1), 61\u201373 (2009).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"4","key":"33979_CR42","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/npp.2009.202","volume":"35","author":"E Hollander","year":"2010","unstructured":"Hollander, E. et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 35(4), 990\u2013998 (2010).","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"33979_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1399-5618.2010.00850.x","volume":"12","author":"MN Pavuluri","year":"2010","unstructured":"Pavuluri, M. N. et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord. 12(6), 593\u2013605 (2010).","journal-title":"Bipolar Disord."},{"issue":"4","key":"33979_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/1039856217711053","volume":"25","author":"N O\u2019Connor","year":"2017","unstructured":"O\u2019Connor, N. & Corish, J. Pharmacological management of acute severe behavioural disturbance: A survey of current protocols. Australas. Psychiatry 25(4), 395\u2013398 (2017).","journal-title":"Australas. Psychiatry"},{"issue":"1","key":"33979_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/cap.2015.0167","volume":"26","author":"T Gurnani","year":"2016","unstructured":"Gurnani, T., Ivanov, I. & Newcorn, J. H. Pharmacotherapy of aggression in child and adolescent psychiatric disorders. J. Child Adolesc. Psychopharmacol. 26(1), 65\u201373 (2016).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"2","key":"33979_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/070674371506000202","volume":"60","author":"T Pringsheim","year":"2015","unstructured":"Pringsheim, T., Hirsch, L., Gardner, D. & Gorman, D. A. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can. J. Psychiatry. 60(2), 42\u201351 (2015).","journal-title":"Can. J. Psychiatry."},{"issue":"3","key":"33979_CR47","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ncprheum0732","volume":"4","author":"A Finckh","year":"2008","unstructured":"Finckh, A. & Tram\u00e8r, M. R. Primer: Strengths and weaknesses of meta-analysis. Nat. Clin. Pract. Rheumatol. 4(3), 146\u2013152 (2008).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"10047","key":"33979_CR48","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(16)30385-3","volume":"388","author":"A Cipriani","year":"2016","unstructured":"Cipriani, A. et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: A network meta-analysis. Lancet 388(10047), 881\u2013890 (2016).","journal-title":"Lancet"},{"issue":"1","key":"33979_CR49","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse, B., Chaimani, A. & Li, T. Network meta-analysis: An introduction for clinicians. Intern. Emerg. Med. 12(1), 103\u2013111 (2017).","journal-title":"Intern. Emerg. Med."},{"issue":"4","key":"33979_CR50","first-page":"951","volume":"15","author":"IR White","year":"2015","unstructured":"White, I. R. Network meta-analysis. Stand. Genom. Sci. 15(4), 951\u2013985 (2015).","journal-title":"Stand. Genom. Sci."},{"issue":"5","key":"33979_CR51","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int. J. Surg. 8(5), 336\u2013341 (2010).","journal-title":"Int. J. Surg."},{"issue":"4","key":"33979_CR52","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3163\/1536-5050.104.4.009","volume":"104","author":"M Vassar","year":"2016","unstructured":"Vassar, M., Atakpo, P. & Kash, M. J. Manual search approaches used by systematic reviewers in dermatology. J. Med. Libr. Assoc. JMLA. 104(4), 302 (2016).","journal-title":"J. Med. Libr. Assoc. JMLA."},{"issue":"2","key":"33979_CR53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1207\/s15374424jccp2702_5","volume":"27","author":"EV Brestan","year":"1998","unstructured":"Brestan, E. V. & Eyberg, S. M. Effective psychosocial treatments of conduct-disordered children and adolescents: 29 years, 82 studies, and 5,272 kids. J. Clin. Child Psychol. 27(2), 180\u2013189 (1998).","journal-title":"J. Clin. Child Psychol."},{"key":"33979_CR54","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins, J. P. et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343, 5928 (2011).","journal-title":"BMJ"},{"issue":"1","key":"33979_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker, G. & Schwarzer, G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med. Res. Methodol. 15(1), 1\u20139 (2015).","journal-title":"BMC Med. Res. Methodol."},{"issue":"4","key":"33979_CR56","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen, J. P. et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health. 14(4), 417\u2013428 (2011).","journal-title":"Value Health."},{"issue":"5","key":"33979_CR57","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias, S., Sutton, A. J., Ades, A. & Welton, N. J. Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med. Decis. Making 33(5), 607\u2013617 (2013).","journal-title":"Med. Decis. Making"},{"issue":"19","key":"33979_CR58","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.7150\/thno.21815","volume":"7","author":"R You","year":"2017","unstructured":"You, R. et al. The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from two\/three-dimensional radiotherapy to intensity-modulated radiotherapy: A network meta-analysis. Theranostics. 7(19), 4825 (2017).","journal-title":"Theranostics."},{"key":"33979_CR59","unstructured":"Collaboration, C. Cochrane handbook: General methods for Cochrane reviews. Heterogeneity. (2014)."},{"issue":"5","key":"33979_CR60","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","volume":"35","author":"L Ribassin-Majed","year":"2017","unstructured":"Ribassin-Majed, L. et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J. Clin. Oncol. 35(5), 498 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"33979_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-131","volume":"14","author":"U Krahn","year":"2014","unstructured":"Krahn, U., Binder, H. & K\u00f6nig, J. Visualizing inconsistency in network meta-analysis by independent path decomposition. BMC Med. Res. Methodol. 14(1), 1\u201312 (2014).","journal-title":"BMC Med. Res. Methodol."},{"issue":"12","key":"33979_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115065","volume":"9","author":"B Neupane","year":"2014","unstructured":"Neupane, B., Richer, D., Bonner, A. J., Kibret, T. & Beyene, J. Network meta-analysis using R: A review of currently available automated packages. PLoS ONE 9(12), e115065 (2014).","journal-title":"PLoS ONE"},{"issue":"10","key":"33979_CR63","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JA Sterne","year":"2001","unstructured":"Sterne, J. A. & Egger, M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J. Clin. Epidemiol. 54(10), 1046\u20131055 (2001).","journal-title":"J. Clin. Epidemiol."},{"issue":"2","key":"33979_CR64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti, G., Ades, A. & Ioannidis, J. P. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial. J. Clin. Epidemiol. 64(2), 163\u2013171 (2011).","journal-title":"J. Clin. Epidemiol."},{"key":"33979_CR65","doi-asserted-by":"crossref","unstructured":"Najafi, Z., Taghadosi, M., Sharifi, K., Farrokhian, A., Tagharrobi, Z. The effects of inhalation aromatherapy on anxiety in patients with myocardial infarction: A randomized clinical trial. Iran. Red Crescent Med. J. 16(8) (2014).","DOI":"10.5812\/ircmj.15485"},{"key":"33979_CR66","unstructured":"Pappadopulos, E., Woolston, S., Chait, A., Perkins, M., Connor, D. F., Jensen, P. S. Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size. J. Can. Acad. Child Adolesc. Psychiatry\/Journal de l'Acad\u00e9mie canadienne de psychiatrie de l'enfant et de l'adolescent. (2006)."},{"issue":"5","key":"33979_CR67","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4103\/0253-7613.117720","volume":"45","author":"S Sarkar","year":"2013","unstructured":"Sarkar, S. & Grover, S. Antipsychotics in children and adolescents with schizophrenia: A systematic review and meta-analysis. Indian J. Pharmacol. 45(5), 439 (2013).","journal-title":"Indian J. Pharmacol."},{"issue":"4","key":"33979_CR68","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.pedhc.2011.02.008","volume":"26","author":"A Sharma","year":"2012","unstructured":"Sharma, A. & Shaw, S. R. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: A meta-analysis. J. Pediatr. Health Care 26(4), 291\u2013299 (2012).","journal-title":"J. Pediatr. Health Care"},{"issue":"1","key":"33979_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-021-01669-0","volume":"19","author":"GL D\u2019Al\u00f2","year":"2021","unstructured":"D\u2019Al\u00f2, G. L. et al. Impact of antipsychotics in children and adolescents with autism spectrum disorder: A systematic review and meta-analysis. Health Qual. Life Outcomes 19(1), 1\u201319 (2021).","journal-title":"Health Qual. Life Outcomes"},{"issue":"4","key":"33979_CR70","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00787-009-0054-3","volume":"19","author":"SV Faraone","year":"2010","unstructured":"Faraone, S. V. & Buitelaar, J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur. Child Adolesc. Psychiatry 19(4), 353\u2013364 (2010).","journal-title":"Eur. Child Adolesc. Psychiatry"},{"issue":"6","key":"33979_CR71","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/jcpp.13305","volume":"62","author":"R Rodrigues","year":"2021","unstructured":"Rodrigues, R. et al. Practitioner review: Pharmacological treatment of attention-deficit\/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: A systematic review and meta-analysis. J. Child Psychol. Psychiatry 62(6), 680\u2013700 (2021).","journal-title":"J. Child Psychol. Psychiatry"},{"issue":"4","key":"33979_CR72","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/aur.2059","volume":"12","author":"S Patra","year":"2019","unstructured":"Patra, S., Nebhinani, N., Viswanathan, A. & Kirubakaran, R. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis. Autism Res. 12(4), 542\u2013552 (2019).","journal-title":"Autism Res."},{"issue":"5","key":"33979_CR73","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1089\/cap.2015.0125","volume":"26","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette\u2019s disorder: A meta-analysis. J. Child Adolesc. Psychopharmacol. 26(5), 436\u2013441 (2016).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"7","key":"33979_CR74","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.clinthera.2014.06.001","volume":"36","author":"B Qin","year":"2014","unstructured":"Qin, B. et al. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: A meta-analysis of efficacy and acceptability. Clin. Ther. 36(7), 1087\u2013954.e4 (2014).","journal-title":"Clin. Ther."},{"issue":"1","key":"33979_CR75","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/JCP.0b013e31823f8770","volume":"32","author":"S Comai","year":"2012","unstructured":"Comai, S., Tau, M. & Gobbi, G. The psychopharmacology of aggressive behavior: A translational approach. Part 1 neurobiology. J. Clin. Psychopharmacol. 32(1), 83\u201394 (2012).","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"33979_CR76","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3922\/j.psns.2014.4.20","volume":"7","author":"R Narvaes","year":"2014","unstructured":"Narvaes, R. & Martins de Almeida, R. M. Aggressive behavior and three neurotransmitters: Dopamine, GABA, and serotonin\u2014A review of the last 10 years. Psychol. Neurosci. 7(4), 601 (2014).","journal-title":"Psychol. Neurosci."},{"issue":"6","key":"33979_CR77","first-page":"18","volume":"7","author":"J Yanofski","year":"2010","unstructured":"Yanofski, J. The dopamine dilemma: Using stimulants and antipsychotics concurrently. Psychiatry (Edgmont) 7(6), 18 (2010).","journal-title":"Psychiatry (Edgmont)"},{"issue":"1","key":"33979_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0306-4522(91)90196-U","volume":"41","author":"AA Grace","year":"1991","unstructured":"Grace, A. A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 41(1), 1\u201324 (1991).","journal-title":"Neuroscience"},{"issue":"4","key":"33979_CR79","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF01277656","volume":"104","author":"A Braun","year":"1997","unstructured":"Braun, A., Laruelle, M. & Mouradian, M. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: The effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. J. Neural Transm. 104(4), 341\u2013362 (1997).","journal-title":"J. Neural Transm."},{"issue":"11","key":"33979_CR80","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","volume":"27","author":"A-N Samaha","year":"2007","unstructured":"Samaha, A.-N., Seeman, P., Stewart, J., Rajabi, H. & Kapur, S. \u201cBreakthrough\u201d dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 27(11), 2979\u20132986 (2007).","journal-title":"J. Neurosci."},{"issue":"1","key":"33979_CR81","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF00421218","volume":"34","author":"G Gianutsos","year":"1974","unstructured":"Gianutsos, G., Hynes, M. D., Puri, S. K., Drawbaugh, R. B. & Lal, H. Effect of apomorphine and nigrostriatal lesions on aggression and striatal dopamine turnover during morphine withdrawal: Evidence for dopaminergic supersensitivity in protracted abstinence. Psychopharmacologia 34(1), 37\u201344 (1974).","journal-title":"Psychopharmacologia"},{"issue":"2","key":"33979_CR82","first-page":"774","volume":"288","author":"T Kuroki","year":"1999","unstructured":"Kuroki, T., Meltzer, H. Y. & Ichikawa, J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288(2), 774\u2013781 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"33979_CR83","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00213-009-1578-4","volume":"206","author":"A M\u00f8rk","year":"2009","unstructured":"M\u00f8rk, A., Witten, L. M. & Arnt, J. Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: A comparison with risperidone and exploration of mechanisms involved. Psychopharmacology 206(1), 39\u201349 (2009).","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"33979_CR84","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0304-3940(89)90289-9","volume":"99","author":"B Westerink","year":"1989","unstructured":"Westerink, B. & De Vries, J. On the mechanism of neuroleptic induced increase in striatal dopamine release: Brain dialysis provides direct evidence for mediation by autoreceptors localized on nerve terminals. Neurosci. Lett. 99(1\u20132), 197\u2013202 (1989).","journal-title":"Neurosci. Lett."},{"issue":"5","key":"33979_CR85","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.neuron.2008.01.022","volume":"57","author":"S Lammel","year":"2008","unstructured":"Lammel, S. et al. Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 57(5), 760\u2013773 (2008).","journal-title":"Neuron"},{"issue":"2","key":"33979_CR86","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00213-005-0170-9","volume":"183","author":"Z Li","year":"2005","unstructured":"Li, Z. et al. ACP-103, a 5-HT2A\/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology 183(2), 144\u2013153 (2005).","journal-title":"Psychopharmacology"},{"issue":"6","key":"33979_CR87","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/j.1471-4159.2005.03485.x","volume":"95","author":"A Bortolozzi","year":"2005","unstructured":"Bortolozzi, A., D\u00edaz-Mataix, L., Scorza, M. C., Celada, P. & Artigas, F. The activation of 5-HT2A receptors in prefrontal cortex enhances dopaminergic activity. J. Neurochem. 95(6), 1597\u20131607 (2005).","journal-title":"J. Neurochem."},{"key":"33979_CR88","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0920-9964(98)00163-7","volume":"35","author":"J Volavka","year":"1999","unstructured":"Volavka, J. & Citrome, L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: Methodological concerns. Schizophr. Res. 35, S23\u2013S33 (1999).","journal-title":"Schizophr. Res."},{"issue":"1","key":"33979_CR89","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00002018-200124010-00005","volume":"24","author":"T Wetterling","year":"2001","unstructured":"Wetterling, T. Bodyweight gain with atypical antipsychotic. Drug Saf. 24(1), 59\u201373 (2001).","journal-title":"Drug Saf."},{"issue":"4","key":"33979_CR90","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13543","volume":"230","author":"F Reichmann","year":"2020","unstructured":"Reichmann, F. et al. The zebrafish histamine H3 receptor modulates aggression, neural activity and forebrain functional connectivity. Acta Physiol. 230(4), e13543 (2020).","journal-title":"Acta Physiol."},{"issue":"6","key":"33979_CR91","doi-asserted-by":"publisher","first-page":"R243","DOI":"10.1016\/j.cub.2014.02.017","volume":"24","author":"HJ Pavlou","year":"2014","unstructured":"Pavlou, H. J., Neville, M. C. & Goodwin, S. F. Aggression: Tachykinin is all the rage. Curr. Biol. 24(6), R243\u2013R244 (2014).","journal-title":"Curr. Biol."},{"issue":"2","key":"33979_CR92","first-page":"711","volume":"297","author":"FI Tarazi","year":"2001","unstructured":"Tarazi, F. I., Zhang, K. & Baldessarini, R. J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 297(2), 711\u2013717 (2001).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"33979_CR93","doi-asserted-by":"publisher","first-page":"c3515","DOI":"10.1136\/bmj.c3515","volume":"341","author":"E N\u00fcesch","year":"2010","unstructured":"N\u00fcesch, E. et al. Small study effects in meta-analyses of osteoarthritis trials: Meta-epidemiological study. BMJ 341, c3515 (2010).","journal-title":"BMJ"},{"issue":"12","key":"33979_CR94","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.rasd.2013.08.012","volume":"7","author":"AJ Kaat","year":"2013","unstructured":"Kaat, A. J. & Lecavalier, L. Disruptive behavior disorders in children and adolescents with autism spectrum disorders: A review of the prevalence, presentation, and treatment. Res. Autism Spectr. Disord. 7(12), 1579\u20131594 (2013).","journal-title":"Res. Autism Spectr. Disord."},{"issue":"7","key":"33979_CR95","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/aur.1968","volume":"11","author":"RY Cai","year":"2018","unstructured":"Cai, R. Y., Richdale, A. L., Uljarevi\u0107, M., Dissanayake, C. & Samson, A. C. Emotion regulation in autism spectrum disorder: Where we are and where we need to go. Autism Res. 11(7), 962\u2013978 (2018).","journal-title":"Autism Res."},{"issue":"6","key":"33979_CR96","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2217\/npy.11.69","volume":"1","author":"AC Swann","year":"2011","unstructured":"Swann, A. C. Antisocial personality and bipolar disorder: Interactions in impulsivity and course of illness. Neuropsychiatry 1(6), 599 (2011).","journal-title":"Neuropsychiatry"},{"key":"33979_CR97","doi-asserted-by":"crossref","unstructured":"Buchmann, A., Hohmann, S., Brandeis, D., Banaschewski, T., Poustka, L. Aggression in children and adolescents. Neurosci. Aggress. 421\u2013442 (2014).","DOI":"10.1007\/7854_2013_261"},{"issue":"3","key":"33979_CR98","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0962280207080643","volume":"17","author":"G Salanti","year":"2008","unstructured":"Salanti, G., Higgins, J. P., Ades, A. & Ioannidis, J. P. Evaluation of networks of randomized trials. Stat. Methods Med. Res. 17(3), 279\u2013301 (2008).","journal-title":"Stat. Methods Med. Res."},{"issue":"7","key":"33979_CR99","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.paid.2012.07.011","volume":"53","author":"MM Martel","year":"2012","unstructured":"Martel, M. M., Gremillion, M. L. & Roberts, B. Temperament and common disruptive behavior problems in preschool. Personal. Individ. Differ. 53(7), 874\u2013879 (2012).","journal-title":"Personal. Individ. Differ."},{"issue":"3","key":"33979_CR100","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1017\/S0954579413000199","volume":"25","author":"SL Olson","year":"2013","unstructured":"Olson, S. L. et al. Deconstructing the externalizing spectrum: Growth patterns of overt aggression, covert aggression, oppositional behavior, impulsivity\/inattention, and emotion dysregulation between school entry and early adolescence. Dev. Psychopathol. 25(3), 817\u2013842 (2013).","journal-title":"Dev. Psychopathol."},{"issue":"3","key":"33979_CR101","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1207\/s15374424jccp2703_10","volume":"27","author":"OG Bukstein","year":"1998","unstructured":"Bukstein, O. G. & Kolko, D. J. Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder. J. Clin. Child Psychol. 27(3), 340\u2013351 (1998).","journal-title":"J. Clin. Child Psychol."},{"issue":"2","key":"33979_CR102","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1037\/1064-1297.9.2.163","volume":"9","author":"SW Evans","year":"2001","unstructured":"Evans, S. W. et al. Dose\u2013response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp. Clin. Psychopharmacol. 9(2), 163 (2001).","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"11","key":"33979_CR103","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1097\/chi.0b013e31814b8d3b","volume":"46","author":"RL Findling","year":"2007","unstructured":"Findling, R. L. et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit\/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 46(11), 1445\u20131453 (2007).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"7","key":"33979_CR104","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/01.chi.0000214191.57993.dd","volume":"45","author":"EB Gorman","year":"2006","unstructured":"Gorman, E. B., Klorman, R., Thatcher, J. E. & Borgstedt, A. D. Effects of methylphenidate on subtypes of attention-deficit\/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 45(7), 808\u2013816 (2006).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"3","key":"33979_CR105","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1023\/A:1005548619694","volume":"30","author":"BL Handen","year":"2000","unstructured":"Handen, B. L., Johnson, C. R. & Lubetsky, M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J. Autism Dev. Disord. 30(3), 245\u2013255 (2000).","journal-title":"J. Autism Dev. Disord."},{"issue":"3","key":"33979_CR106","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1089\/cap.2020.0104","volume":"31","author":"Y-S Huang","year":"2021","unstructured":"Huang, Y.-S., Yeh, C.-B., Chen, C.-H., Shang, C.-Y. & Gau, S.S.-F. A randomized, double-blind, placebo-controlled, two-way crossover clinical trial of ORADUR-methylphenidate for treating children and adolescents with attention-deficit\/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 31(3), 164\u2013178 (2021).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"5","key":"33979_CR107","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/00004583-199009000-00007","volume":"29","author":"SL Kaplan","year":"1990","unstructured":"Kaplan, S. L., Busner, J., Kupietz, S., Wassermann, E. & Segal, B. Effects of methylphenidate on adolescents with aggressive conduct disorder and ADDH: A preliminary report. J. Am. Acad. Child Adolesc. Psychiatry 29(5), 719\u2013723 (1990).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"12","key":"33979_CR108","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/archpsyc.1997.01830240023003","volume":"54","author":"RG Klein","year":"1997","unstructured":"Klein, R. G. et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch. Gen. Psychiatry 54(12), 1073\u20131080 (1997).","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"33979_CR109","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/00004583-199905000-00020","volume":"38","author":"DJ Kolko","year":"1999","unstructured":"Kolko, D. J., Bukstein, O. G. & Barron, J. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: Main and incremental effects across settings. J. Am. Acad. Child Adolesc. Psychiatry 38(5), 578\u2013586 (1999).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"6","key":"33979_CR110","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1542\/peds.104.6.1300","volume":"104","author":"WE Pelham","year":"1999","unstructured":"Pelham, W. E. et al. A comparison of morning-only and morning\/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit\/hyperactivity disorder. Pediatrics 104(6), 1300\u20131311 (1999).","journal-title":"Pediatrics"},{"issue":"2","key":"33979_CR111","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1037\/1064-1297.13.2.111","volume":"13","author":"WE Pelham","year":"2005","unstructured":"Pelham, W. E. et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp. Clin. Psychopharmacol. 13(2), 111 (2005).","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"7","key":"33979_CR112","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/00004583-200007000-00021","volume":"39","author":"SR Pliszka","year":"2000","unstructured":"Pliszka, S. R. et al. The Texas Children\u2019s Medication Algorithm Project: Report of the Texas Consensus Conference Panel on medication treatment of childhood attention-deficit\/hyperactivity disorder. Part I. J. Am. Acad. Child Adolesc. Psychiatry. 39(7), 908\u2013919 (2000).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry."},{"issue":"4","key":"33979_CR113","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2006.09.028","volume":"61","author":"DJ Posey","year":"2007","unstructured":"Posey, D. J. et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures. Biol. Psychiat. 61(4), 538\u2013544 (2007).","journal-title":"Biol. Psychiat."},{"issue":"4","key":"33979_CR114","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1089\/cap.2007.0011","volume":"17","author":"J Sinzig","year":"2007","unstructured":"Sinzig, J., D\u00f6pfner, M., Lehmkuhl, G. & Group, G. M. S. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit\/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 17(4), 421\u2013432 (2007).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"4","key":"33979_CR115","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1542\/peds.108.4.883","volume":"108","author":"ML Wolraich","year":"2001","unstructured":"Wolraich, M. L. et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit\/hyperactivity disorder. Pediatrics 108(4), 883\u2013892 (2001).","journal-title":"Pediatrics"},{"issue":"10","key":"33979_CR116","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","volume":"45","author":"LE Arnold","year":"2006","unstructured":"Arnold, L. E. et al. Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J. Am. Acad. Child Adolesc. Psychiatry 45(10), 1196\u20131205 (2006).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"2","key":"33979_CR117","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/cap.2009.0111","volume":"21","author":"RW Dittmann","year":"2011","unstructured":"Dittmann, R. W. et al. Atomoxetine versus placebo in children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder: A double-blind, randomized, multicenter trial in Germany. J. Child Adolesc. Psychopharmacol. 21(2), 97\u2013110 (2011).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"4","key":"33979_CR118","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1089\/cap.2006.0091","volume":"17","author":"SS Gau","year":"2007","unstructured":"Gau, S. S. et al. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine hydrochloride in Taiwanese children and adolescents with attention-deficit\/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 17(4), 447\u2013460 (2007).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"2","key":"33979_CR119","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/108705470400800202","volume":"8","author":"S Kaplan","year":"2004","unstructured":"Kaplan, S. et al. Efficacy and safety of atomoxetine in childhood attention-deficit\/hyperactivity disorder with comorbid oppositional defiant disorder. J. Atten. Disord. 8(2), 45\u201352 (2004).","journal-title":"J. Atten. Disord."},{"issue":"5","key":"33979_CR120","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.5.e83","volume":"108","author":"D Michelson","year":"2001","unstructured":"Michelson, D. et al. Atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108(5), e83-e (2001).","journal-title":"Pediatrics"},{"issue":"11","key":"33979_CR121","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1176\/appi.ajp.159.11.1896","volume":"159","author":"D Michelson","year":"2002","unstructured":"Michelson, D. et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am. J. Psychiatry 159(11), 1896\u20131901 (2002).","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"33979_CR122","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/01.chi.0000125089.35109.81","volume":"43","author":"D Michelson","year":"2004","unstructured":"Michelson, D. et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry 43(7), 896\u2013904 (2004).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"11","key":"33979_CR123","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1185\/03007990903316152","volume":"25","author":"A Montoya","year":"2009","unstructured":"Montoya, A. et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit\/hyperactivity disorder. Curr. Med. Res. Opin. 25(11), 2745\u20132754 (2009).","journal-title":"Curr. Med. Res. Opin."},{"issue":"7","key":"33979_CR124","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/01.chi.0000163280.47221.c9","volume":"44","author":"M Weiss","year":"2005","unstructured":"Weiss, M. et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 44(7), 647\u2013655 (2005).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"2","key":"33979_CR125","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/1044546041649020","volume":"14","author":"MG Aman","year":"2004","unstructured":"Aman, M. G., Binder, C. & Turgay, A. Risperidone effects in the presence\/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J. Child Adolesc. Psychopharmacol. 14(2), 243\u2013254 (2004).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"4","key":"33979_CR126","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1176\/appi.ajp.161.4.677","volume":"161","author":"RL Findling","year":"2004","unstructured":"Findling, R. L. et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am. J. Psychiatry. 161(4), 677\u2013684 (2004).","journal-title":"Am. J. Psychiatry."},{"issue":"5","key":"33979_CR127","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/01.yic.0000166403.03732.72","volume":"20","author":"JC LeBlanc","year":"2005","unstructured":"LeBlanc, J. C. et al. Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: Analysis of two placebo-controlled randomized trials. Int. Clin. Psychopharmacol. 20(5), 275\u2013283 (2005).","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"33979_CR128","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","volume":"37","author":"GJ Pandina","year":"2007","unstructured":"Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y. & Dunbar, F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J. Autism Dev. Disord. 37(2), 367\u2013373 (2007).","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"33979_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5812\/ijp.60087","volume":"28","author":"K Razjouyan","year":"2018","unstructured":"Razjouyan, K., Danesh, A., Khademi, M., Davari-Ashtiani, R. & Noorbakhsh, S. A comparative study of risperidone and aripiprazole in attention deficit hyperactivity disorder in children under six years old: A randomized double-blind study. Iran. J. Pediatr. 28(1), 1\u20138 (2018).","journal-title":"Iran. J. Pediatr."},{"issue":"3","key":"33979_CR130","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","volume":"163","author":"M Reyes","year":"2006","unstructured":"Reyes, M., Buitelaar, J., Toren, P., Augustyns, I. & Eerdekens, M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am. J. Psychiatry 163(3), 402\u2013410 (2006).","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"33979_CR131","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","volume":"114","author":"S Shea","year":"2004","unstructured":"Shea, S. et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114(5), e634\u2013e641 (2004).","journal-title":"Pediatrics"},{"issue":"2","key":"33979_CR132","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/2231-4040.177203","volume":"7","author":"P Safavi","year":"2016","unstructured":"Safavi, P., Hasanpour-Dehkordi, A. & AmirAhmadi, M. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial. J. Adv. Pharm. Technol. Res. 7(2), 43 (2016).","journal-title":"J. Adv. Pharm. Technol. Res."},{"issue":"10","key":"33979_CR133","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","volume":"164","author":"M Tohen","year":"2007","unstructured":"Tohen, M. et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am. J. Psychiatry 164(10), 1547\u20131556 (2007).","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"33979_CR134","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1469-7610.1992.tb00876.x","volume":"33","author":"GA Carlson","year":"1992","unstructured":"Carlson, G. A., Rapport, M. D., Pataki, C. S. & Kelly, K. L. Lithium in hospitalized children at 4 and 8 weeks: Mood, behavior and cognitive effects. J. Child Psychol. Psychiatry 33(2), 411\u2013425 (1992).","journal-title":"J. Child Psychol. Psychiatry"},{"issue":"9","key":"33979_CR135","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/cap.2016.0026","volume":"27","author":"F Sallee","year":"2017","unstructured":"Sallee, F. et al. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette\u2019s disorder in children and adolescents. J. Child Adolesc. Psychopharmacol. 27(9), 771\u2013781 (2017).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"16","key":"33979_CR136","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1001\/jama.2019.14685","volume":"322","author":"DS Reddihough","year":"2019","unstructured":"Reddihough, D. S. et al. Effect of fluoxetine on obsessive-compulsive behaviors in children and adolescents with autism spectrum disorders: A randomized clinical trial. JAMA 322(16), 1561\u20131569 (2019).","journal-title":"JAMA"},{"key":"33979_CR137","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3389\/fpsyt.2019.00810","volume":"10","author":"LA Potter","year":"2019","unstructured":"Potter, L. A. et al. A randomized controlled trial of sertraline in young children with autism spectrum disorder. Front. Psychiatry. 10, 810 (2019).","journal-title":"Front. Psychiatry."},{"issue":"4","key":"33979_CR138","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/00004583-199604000-00014","volume":"35","author":"JE Cueva","year":"1996","unstructured":"Cueva, J. E. et al. Carbamazepine in aggressive children with conduct disorder: A double-blind and placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry 35(4), 480\u2013490 (1996).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"4","key":"33979_CR139","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/cap.2005.15.682","volume":"15","author":"JA Hellings","year":"2005","unstructured":"Hellings, J. A. et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 15(4), 682\u2013692 (2005).","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"33979_CR140","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/00004583-199201000-00005","volume":"31","author":"RG Klein","year":"1992","unstructured":"Klein, R. G., Koplewicz, H. S. & Kanner, A. Imipramine treatment of children with separation anxiety disorder. J. Am. Acad. Child Adolesc. Psychiatry 31(1), 21\u201328 (1992).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"1","key":"33979_CR141","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/(SICI)1520-6394(1998)7:1<15::AID-DA3>3.0.CO;2-4","volume":"7","author":"RG Klein","year":"1998","unstructured":"Klein, R. G. et al. Adolescent depression: Controlled desipramine treatment and atypical features. Depress. Anxiety 7(1), 15\u201331 (1998).","journal-title":"Depress. Anxiety"},{"issue":"7","key":"33979_CR142","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/archpsyc.59.7.649","volume":"59","author":"T Spencer","year":"2002","unstructured":"Spencer, T. et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit\/hyperactivity disorder. Arch. Gen. Psychiatry 59(7), 649\u2013656 (2002).","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"33979_CR143","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/cap.2018.0083","volume":"29","author":"RL Findling","year":"2019","unstructured":"Findling, R. L. et al. Dasotraline in children with attention-deficit\/hyperactivity disorder: A six-week, placebo-controlled, fixed-dose trial. J. Child Adolesc. Psychopharmacol. 29(2), 80\u201389 (2019).","journal-title":"J. Child Adolesc. Psychopharmacol."}],"updated-by":[{"DOI":"10.1038\/s41598-023-51047-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33979-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33979-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33979-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T08:09:46Z","timestamp":1704787786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33979-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":143,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33979"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33979-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-023-51047-7","URL":"https:\/\/doi.org\/10.1038\/s41598-023-51047-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6921"}}